At a glance
ClinicalIndex Comparison RecordN/ACompleted· 299 enrolled / 299 target
Drug / intervention
JARDIANCE®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Regulatory Non-interventional Study to Monitor the Safety and Efficacy of JARDIANCE® (Empagliflozin 10 mg) in Korean Patients With Chronic Kidney Disease (CKD)
In Brief
An observational study evaluating JARDIANCE® for Kidney Disease, Chronic. Completed, enrolled 299 participants across 12 sites.
Detailed Summary
The primary objective is to monitor the safety profile of JARDIANCE® in Korean patient with chronic kidney disease (CKD) in routine clinical practice. The secondary objective is to monitor the efficacy of JARDIANCE® by evaluating changes in urine albumin-creatinine ratio (UACR) after 12 and/or 24 weeks of treatment.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Disease, Chronic
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
20252026
First PostedFeb 2024
Enrollment StartMar 2024
Primary CompletionApr 2025
TodayJul 2026
First PostedFeb 29, 2024
Enrollment StartMar 29, 2024
Primary CompletionApr 30, 2025
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 2.3 years ago
Arms & Interventions
JARDIANCE® treated patientsother
Patients with chronic kidney disease (CKD) who started JARDIANCE® for the first time in accordance with the approved label in Korea, treated according to routine clinical practice.
Drug: JARDIANCE®
Interventions
JARDIANCE®drug
JARDIANCE®